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Abstract. irritable bowel syndrome (iBS) affects ~12% of the 
global population. although the etiology of iBS is not completely 
understood, several factors are known to serve a pivotal role in 
its pathophysiology, including genetic factors, diet, the intestinal 
microbiota, gastrointestinal endocrine cells and low-grade 
inflammation. Musashi‑1 is expressed by stem cells and their 
early progeny, and is used as a stem cell marker. The low density 
of intestinal endocrine cells in patients with iBS is thought to 
be caused by decreased numbers of intestinal stem cells and 
their differentiation into enteroendocrine cells. The present 
study employed Musashi-1 as a marker to detect stem cells in 
the stomach of 54 patients with iBS and 51 healthy subjects. 
The patients and controls underwent standard gastroscopy, 
and biopsy samples were taken from the corpus and antrum. 
immunohistochemical staining of gastrin, somatostatin and 
Mushasi‑1 was carried out and semi‑quantified by computerized 
image analysis. The density (number of positive cells/mm2 epithe-
lium) of gastrin-positive cells in the controls and patients with 
iBS were 337.9±560 and 531.0±908 (median ± range; P<0.0001), 
respectively. For somatostatin-positive cells, the density reached 
364.4±526.0 in the healthy controls and 150.7±514.0 in patients 
with iBS (P<0.0001). The density of Musashi-1-positive cells was 
defined as the number of cells per gastric or pyloric gland neck. 
in the corpus, Musashi-1-positive cells density reached 3.0±7.0 
in the corpus of the healthy controls and 3.8±7.7 in the patients 
with iBS. Moreover, the corresponding values in the antrum 
were 6.0±6.0 and 6.0±6.0, respectively. The Musashi-1-positive 
cell density did not differ significantly between the controls 
and patients with iBS in the corpus or antrum (P=0.4 and 
0.3, respectively). These findings indicated that changes in the 
stomach endocrine cells observed in patients with iBS may not 
be explained by an abnormality in stem cells like those found in 
the small and large intestines of these patients.
Introduction
irritable bowel syndrome (iBS) is a common gastrointestinal 
disorder with unclear pathophysiology (1,2). However, several 
factors are known to contribute to the pathophysiology of this 
condition, including genetic factors, diet, the intestinal micro-
biota, enteroendocrine cells and low‑grade inflammation (1‑4).
Gastrointestinal endocrine cells produce >10 different 
hormones that regulate several functions of the gastro-
intestinal tract, such as gastrointestinal motility, visceral 
sensitivity, absorption, secretion, proliferation, local immune 
defense and appetite (1,5). The gastrointestinal endocrine 
cells interact and integrate with each other, and with the 
enteric, autonomic and central nervous systems (6). in iBS, 
gastrointestinal motility and secretion are abnormal and 
patients exhibit visceral hypersensitivity (5). The density of 
enteroendocrine cells in patients with iBS has been reported 
to be lower than healthy subjects, which may contribute to the 
pathophysiology of iBS (2,5,7-15).
Previous studies have suggested that the intestinal density 
of Musashi-1- and neurogenin-3-positive cells were reduced in 
patients with iBS (7,13,16). Musashi-1 is a marker for intestinal 
stem cells and their early progeny (17-21). neurogenin-3 is 
expressed by an early progenitor for endocrine cells (22,23). It 
has been proposed that the low density of enteroendocrine cells 
seen in patients with iBS could be caused by this abnormality 
in stem cells and their differentiation into enteroendocrine 
cells (6,7,9-13,16,24-26). Furthermore, the role of genetic 
factors, diet, intestinal microbiota, enteroendocrine cells and 
low-grade inflammation in the pathophysiology of iBS is 
likely mediated through intestinal stem cells (27).
The density of endocrine cells in the stomach corpus is 
similar in patients with iBS and healthy subjects (28,29). 
However, the density of gastrin-positive cells in the stomach 
antrum has been reported to be higher, whereas the density 
of somatostatin-positive cells has been reported to be lower in 
patients with iBS, compared with healthy subjects (30). These 
differences may explain the high incidence of erosive esopha-
gitis observed in patients with iBS (31), as gastrin stimulates 
acid secretion and somatostatin inhibits acid secretion (6).
The aim of the present study was to investigate whether the 
changes in the density of gastrin- and somatostatin-positive in 
the stomach of patients with iBS were associated with altera-
tions in stem cells.
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Materials and methods
Patients and controls. Patients with iBS (n=54), according 
to the rome iV criteria (32), were recruited from an outpa-
tient clinic at Stord Hospital (Stord, norway). a control 
group was formed from healthy subjects (n=51) without any 
gastrointestinal complaints recruited through an announce-
ment in the local newspaper. The controls comprised 38 
females and 13 males with a mean age of 38 years (range, 
20-67 years).The characteristics of the patients with iBS 
are provided in Table I. Co‑existence of other functional 
gastrointestinal disorders was not recorded in the patients 
with iBS included in the study. The present study was 
approved by The regional committee for Medical and 
Health research ethics West (approval no. 2017/1197/reK 
Vest). all participants gave oral and written consent to 
participate.
Gastroscopy and histopathology. Both the patients and 
controls underwent standard gastroscopy after an overnight 
fast. Three biopsy samples were taken from the antrum and 
three from the corpus (major curvature) of the stomach. 
Two additional biopsies were taken from the antrum and 
analyzed in a rapid urease test for Helicobacter pylori 
(HelicotecuT Plus, Strong Biotech corp.). The two biopsy 
samples were placed in polystyrene gel containing urea 
substrate for 1 h at room temperature. in the presence of 
Helicobacter pylori urease hydrolysis urea to produce 
ammonia and co2, which changes the pH and is detected 
as a change in the color of the gel from yellow to red. The 
biopsy samples were fixed in 4% buffered paraformalde-
hyde at room temperature overnight, embedded in paraffin 
wax, then cut into 5‑µm sections that were stained with 
hematoxylin for 20 sec and eosin at room temperature 
for 3‑4 min and were examined under a light microscope 
(olympus BX43, olympus corporation).
Immunohis tochemis t r y  and computer ized image 
analysis. The sections were immunostained using the 
avidin‑biotin‑complex (ABC) method with the Vectastain® 
elite aBc-HrP kit (cat. no. PK-6200, Vector laboratories, 
inc.). The sections were incubated for 20 min with the 
blocking normal horse serum then with the primary anti-
bodies at room temperature overnight. The sections were 
incubated with the secondary biotinylated horse anti-rabbit 
igG antibody for 30 min at room temperature followed by 
the Avidin‑bioytin complex for 30 min at room tempera-
ture. The following polyclonal rabbit primary antibodies 
were used: anti-human gastrin-17 (cat. no. ir519; 1:500; 
dako; agilent Technologies, inc.); anti-synthetic cyclic 
(amino-acid sequence 1-14) somatostatin (cat. no. a0566; 
1:200; dako; agilent Technologies, inc.); and an antibody 
raised against a synthetic peptide derived from human 
Musashi-1 (amino acids 1-100; internal sequence) conju-
gated to keyhole limpet haemocyanin (cat. no. ab21628; 
1:100; abcam).
The density of Musashi-1-positive cells was semi-quan-
tified on a computer linked to a BX43 light microscope 
equipped with a dP26 digital camera using olympus 
cellSens imaging software (version 1.7; all from olympus 
corporation). The number of Musashi-1-immunoreactive 
cells, and the number of gastric or pyloric gland necks in 
each field were counted manually by pointing and clicking 
the computer mouse in ten randomly chosen fields. A x400 
magnification was used and each field on the monitor 
represented a tissue area of 0.14 mm2. The data from the 
fields were tabulated, and the cell density was expressed as 
the number of cells per gastric or pyloric gland neck. The 
number of gastrin- or somatostatin-immunoreactive cells, 
and the area of epithelial cells were measured using the 
same system in 10 randomly chosen fields. The density of 
gastrin‑ and somatostatin‑positive cells were expressed as 
number of cells/mm2 epithelium. immunostained sections 
from the patients with iBS and controls were coded and 
mixed, with measurements made by an investigator who was 
blind to the identity of the sections.
Statistical analysis. The χ2 test was used to assess differences 
between the patients and controls with regards to sex and the 
incidence of H. pylori infection. differences in age, and in the 
densities of gastrin-, somatostatin-, and Musashi-1-positive 
cells were tested using the Mann-Whitney nonparametric 
test. The statistical analyses were performed using GraphPad 
Prism software (version 8; GraphPad Software, inc.). P<0.05 
was considered to indicate a statistically significant difference.
Results
Patients and controls. The sex and age distributions did not 
differ significantly between the patients with iBS and the 
controls (P=0.9 and 0.8, respectively). The urease test and 
histopathological examination indicated H. pylori infection in 
three patients and two controls, also with no significant differ-
ence between the groups (P=0.6; Table i).
Gastroscopy and histopathology. Gastroscopy suggested that 
the esophagus, stomach and duodenum were all macroscopi-
cally normal in both groups. A histopathological examination 
of the corpus and antrum indicated normal histology, with the 
exception of individuals with H. pylori infection, in whom 
metaplasia was found in the antrum.
Immunohistochemistry and computerized image analysis. 
The gastrin-positive cell density in the controls and patients 
with iBS were 303.0±560.0 and 623.0±668.0 (median ± range; 
P<0.0001), respectively (Fig. 1). The corresponding figures 
for somatostatin-positive cell density were 302.0±526.0 and 
140.0±514.0 (P<0.0001; Fig. 2).
Musashi-1-immunoreactive cells were concentrated at the 
necks of the gastric glands of the corpus and of the pyloric 
glands of the antrum, where they were evident mostly in a 
clonogenic proliferation or differentiation form (Fig. 3). 
The density of Musashi-1-positive cells in the corpus was 
6.0±6.0 in the controls and 6.0±6.0 in the patients with 
iBS (P=0.4); the corresponding values in the antrum were 
3.0±7.0 and, 3.8±7.7 respectively (P=0.3; Fig. 4). a subgroup 
analysis based on the phenotype of the disorder (diarrhea 
predominant, constipation predominant or mixed type) was 
not performed, as the number of patients in these subgroups 
was too small to allow reliable analysis.
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Discussion
The stomach is divided anatomically into the corpus and 
antrum, each comprising different cells and functions (33). 
The gastric glands of the corpus contain mucous neck 
cells, parietal cells, chief cells and endocrine cells. in the 
antrum, endocrine cells and mucous cells are the main cell 
types in the pyloric glands (33,34). While serotonin- and 
Figure 2. Somatostatin-positive-cells (arrows) in (a) a healthy control and in (B) a patient with iBS. (c) densities of somatostatin-immunoreactive cells in the epithe-
lium of patients with IBS and healthy controls. Scale, 20 µm. ****P<0.0001. data are presented as the median ± interquartile range. iBS, irritable bowel syndrome.
Figure 1. Gastrin-positive-cells (arrows) in (a) a healthy control and in (B) a patient with iBS. (c) densities of gastrin immunoreactive cells in the epithelium 
of patients with IBS and healthy controls. Scale, 20 µm. ****P<0.0001. data are presented as the median and interquartile range. iBS, irritable bowel syndrome.
Table i. characteristics of the controls and patients with iBS.
clinicopathological variable control group, n=51 iBS group, n=54
age, mean (range) years 36 (20-64) 32 (18-52)
Sex, n  
  Male 41 44
  Female 10 10
iBS subtype, n  
  iBS-d 0 20
  iBS-c 0 21
  iBS-M 0 13
iBS duration, years (mean ± Sd) 0 15.5±8.0
H. pylori infection 2 3
Medication, n (%)  
  PPi medication 2 (3.9) 53 (98.2)
  Birth control medication 32 (62.8) 42 (77.8)
  antimigraine medication 0 (0.0) 2 (3.7)
  Medication against asthma/allergies 0 (0.0) 3 (5.6)
  Medication with laevothyroxine 0 (0.0) 1 (1.9)
  Medication with heart/vascular drugs 1 (2.0) 0 (0.0)
IBS, irritable bowel syndrome; PPI, proton pump inhibitor; D, diarrhea predominant; C, constipation predominant; M, mixed type.
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somatostatin‑expressing cells are present in both the corpus 
and the antrum, ghrelin-positive cells are present only in the 
oxyntic mucosa of the corpus, while gastrin‑positive cells 
are exclusive to the pyloric glands of the antrum (28,30). 
Several attempts have been made to identify a specific marker 
for gastric stem cells (33). Musashi-1, which is considered a 
marker for intestinal stem cells and their early progeny, is 
reportedly expressed by cells in the corpus and antrum of the 
stomach (35,36).
The present study found that Musashi‑1‑expressing cells 
were mostly present at the necks of the gastric glands of the 
corpus and of the pyloric glands of the antrum, which is 
consistent with previous observations (35,36). The density of 
Musashi-1-positive cells in both the corpus and antrum did 
not differ between patients with iBS and healthy controls. 
These observations may explain why, in a previous study, 
the total density of endocrine cells detected using chromo-
granin a in the corpus and antrum was similar in patients 
with iBS and healthy controls (29). in addition, the densi-
ties of ghrelin‑, serotonin‑ and somatostatin‑expressing 
cells in the oxyntic mucosa of the corpus did not differ 
between patients with iBS and healthy controls in a previous 
study (28). However, the densities of gastrin-positive cells 
were higher and somatostatin-positive cells were lower in 
the antrum of patients with iBS, compared with healthy 
controls. These differences could not be explained by 
abnormalities in stem cells like those previously observed 
in the small and large intestines of patients with iBS, where 
density of Musashi-1-positive cells were lower than that of 
healthy controls (2,5,37).
The mechanisms underlying the changes in the densities of 
antral gastrin- and somatostatin-positive cells in patients with 
iBS remain unclear. These changes could represent a response 
to the changes in the intestinal chromogranin a, serotonin, 
secretin, cholecystokinin, gastric inhibitory peptide, soma-
tostatin, peptide YY and enteroglucagon (oxyntomodulin) cells 
seen in these patients (2,5,7-15). The increase in the number 
of gastrin‑expressing cells and the reduction in the number of 
somatostatin‑expressing cells could result from activation of 
gastrin synthesis and inhibition of somatostatin synthesis, a 
phenomenon that has been observed in gastrointestinal endo-
crine cells (38,39). However, the present study was limited to 
measuring changes in densities of gastrin-, somatostatin- and 
Musashi‑1‑expressing cells. The expression or secretion of 
these active substances were not evaluated.
in conclusion, the changes in the density of antral gastrin- 
and somatostatin‑expressing cells in patients with IBS cannot 
be explained by a low density of stem cells; thus as the gut 
endocrine cells integrate and interact with each other, the 
changes in gastrin‑and somatostatin‑expressing cells in 
patients with iBS may be caused by the direct changes in the 
intestinal endocrine cells.
Figure 4. Musashi-1-positive cells (arrows) are present in the necks of the pyloric glands of the antrum. Musashi-1-positive cells in (a) a patient with irritable 
bowel syndrome and (B) in a healthy control. Densities of Musashi‑1‑positive cells in the antrum of patients with IBS and healthy controls (C) Scale, 20 µm. 
iBS, irritable bowel syndrome.
Figure 3. Musashi-1-positive cells (arrows) in the necks of the gastric glands of the corpus in (a) a patient with irritable bowel syndrome and (B) in a healthy 
control. (C) Densities of Musashi‑1‑positive cells in the corpus of patients with IBS and healthy controls. Scale, 20 µm. Data are presented as the median and 
interquartile range. iBS, irritable bowel syndrome.
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